Literature DB >> 8763626

Serotyping, ribotyping, PCR-mediated ribosomal 16S-23S spacer analysis and arbitrarily primed PCR for epidemiological studies on Legionella pneumophila.

A Van Belkum1, H Maas, H Verbrugh, N Van Leeuwen.   

Abstract

Fifty clinical and environmental isolates of Legionella pneumophila were typed serologically and by DNA fingerprinting using arbitrarily primed polymerase chain reaction (AP-PCR). Furthermore, variability in and around ribosomal operons was assessed by conventional ribotyping and PCR-mediated amplification of the spacer region separating the 16S and 23S genes. It appears that serotyping suffers from low resolution capabilities, and ribotyping and spacer PCR display intermediate resolving capabilities, whereas AP-PCR is more discriminating. Results from AP-PCR and both forms of ribotyping analysis correlate with epidemiological and environmental data. It is suggested that AP-PCR typing may be the method of choice for rapidly determining clonality among L. pneumophila isolates.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8763626     DOI: 10.1016/0923-2508(96)84715-2

Source DB:  PubMed          Journal:  Res Microbiol        ISSN: 0923-2508            Impact factor:   3.992


  3 in total

1.  Comparison of three molecular methods used for subtyping of Legionella pneumophila strains isolated during an epidemic of Legionellosis in Rome.

Authors:  M Scaturro; M Losardo; G De Ponte; M L Ricci
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

2.  Antigenic lipopolysaccharide components of Legionella pneumophila recognized by monoclonal antibodies: possibilities and limitations for division of the species into serogroups.

Authors:  J H Helbig; J B Kurtz; M C Pastoris; C Pelaz; P C Lück
Journal:  J Clin Microbiol       Date:  1997-11       Impact factor: 5.948

Review 3.  Legionella and Legionnaires' disease: 25 years of investigation.

Authors:  Barry S Fields; Robert F Benson; Richard E Besser
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.